首页> 美国卫生研究院文献>MedChemComm >Tricyclic xanthine derivatives containing a basic substituent: adenosine receptor affinity and drug-related properties
【2h】

Tricyclic xanthine derivatives containing a basic substituent: adenosine receptor affinity and drug-related properties

机译:含碱性取代基的三环黄嘌呤衍生物:腺苷受体亲和力和药物相关特性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A library of 27 novel amide derivatives of annelated xanthines was designed and synthesized. The new compounds represent 1,3-dipropyl- and 1,3-dibutyl-pyrimido[2,1-f]purinedione-9-ethylphenoxy derivatives including a CH2CONH linker between the (CH2)2-amino group and the phenoxy moiety. A synthetic strategy to obtain the final products was developed involving solvent-free microwave irradiation. The new compounds were evaluated for their adenosine receptor (AR) affinities. The most potent derivatives contained a terminal tertiary amino function. Compounds with nanomolar AR affinities and at the same time high water-solubility were obtained (A1 (Ki = 24–605 nM), A2A (Ki = 242–1250 nM), A2B (Ki = 66–911 nM) and A3 (Ki = 155–1000 nM)). 2-(4-(2-(1,3-Dibutyl-2,4-dioxo-1,2,3,4,7,8-hexahydropyrimido[2,1-f]purin-9(6H)-yl)ethyl)phenoxy)-N-(3-(diethylamino)propyl)acetamide (>27) and the corresponding N-(2-(pyrrolidin-1-yl)ethyl)acetamide (>36) were found to be the most potent antagonists of the present series. While >27 showed CYP inhibition and moderate metabolic stability, >36 was found to possess suitable properties for in vivo applications. In an attempt to explain the affinity data for the synthesized compounds, molecular modeling and docking studies were performed using homology models of A1 and A2A adenosine receptors. The potent compound >36 was used as an example for discussion of the possible ligand–protein interactions. Moreover, the compounds showed high water-solubility indicating that the approach of introducing a basic side chain was successful for the class of generally poorly soluble AR antagonists.
机译:设计并合成了27种新的酰胺化黄嘌呤酰胺衍生物库。新化合物代表在(CH2)2-氨基和苯氧基部分之间包含CH2CONH连接基的1,3-二丙基-和1,3-二丁基-嘧啶[2,1-f]嘌呤二酮-9-乙基苯氧基衍生物。开发了一种获得最终产品的合成策略,其中涉及无溶剂微波辐射。评价了新化合物的腺苷受体(AR)亲和力。最有效的衍生物含有末端叔氨基官能团。获得具有纳摩尔摩尔亲和力且同时具有高水溶性的化合物(A1(Ki = 24–605 nM),A2A(Ki = 242–1250 nM),A2B(Ki = 66–911 nM)和A3(Ki = 155–1000 nM))。 2-(4-(2-(1,3-二丁基-2,4-二氧-1,2,3,4,7,8-六氢嘧啶基[2,1-f]嘌呤-9(6H)-基))乙基)苯氧基)-N-(3-(二乙氨基)丙基)乙酰胺(> 27 )和相应的N-(2-(吡咯烷基-1-基)乙基)乙酰胺(> 36 < / strong>)是本系列中最有效的拮抗剂。虽然> 27 显示出CYP抑制作用和中等的代谢稳定性,但> 36 被发现具有适合体内应用的特性。为了解释合成化合物的亲和力数据,使用A1和A2A腺苷受体的同源性模型进行了分子建模和对接研究。以强效化合物> 36 为例,讨论了可能的配体-蛋白质相互作用。此外,这些化合物显示出高的水溶性,这表明引入基本侧链的方法对于一类通常难溶的AR拮抗剂是成功的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号